Metastatic sacral chordoma

Authors

DOI:

https://doi.org/10.11606/issn.2176-7262.rmrp.2022.195609

Keywords:

Chordoma, Sacrum, Tumor metastasis, Case reports

Abstract

Sacral chordomas (SC) are rare primary malignant bone tumors of the vertebral column, with an incidence between 0.000005-0.000027%. The aim of this study is to describe a case of metastatic SC. A 42-year-old man, without comorbid conditions arrived at the referral center, presenting with a sacral lesion. MRI showed a tumor measuring 9.3 cm that was suggestive of myeloma or chordoma. A biopsy with histopathology study was performed, confirming the diagnosis of SC. The patient underwent surgical tumor excision. Six months after surgery, the tumor recurred with metastatic vertebral column implants, soft tissues of the chest wall, liver and pleural space, and the patient became paraplegic. There was no indication of adjuvant radiotherapy and/or chemotherapy. There was also no possibility that imatinib would be approved by the Unified Health System. At about 28 months of monthly clinical follow-up, the patient died. The case presented showed unsuccessful SC surgery, which is associated with a worse prognosis. The patient had systemic tumor dissemination and paraplegia a few months after surgery, dying at 28 months of follow-up.

Downloads

Download data is not yet available.

Author Biographies

  • Rafael Everton Assunção Ribeiro da Costa, Universidade Estadual do Piauí. Centro de Ciências da Saúde, Teresina (PI), Brasil

    Acadêmico de Medicina

  • Ana Raquel Lopes Visgueira, Universidade Estadual do Piauí. Centro de Ciências da Saúde, Teresina (PI), Brasil

    Acadêmica de Medicina

  • Eugênio de Sá Coutinho Neto, Hospital Macrorregional de Caxias Dr. Everardo Aragão. Unidade de Alta Complexidade em Oncologia, Caxias (MA), Brasil.

    Médico Radiologista

  • Carlos Eduardo Coelho de Sá, Hospital Macrorregional de Caxias Dr. Everardo Aragão. Unidade de Alta Complexidade em Oncologia, Caxias (MA), Brasil.

    Médico oncologista clínico

References

Tenny S, Varacallo M. Chordoma. 2022 Feb 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.

Bakker SH, Jacobs WCH, Pondaag W, Gelderblom H, Nout RA, Dijkstra PDS, et al. Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival. Eur Spine J. 2018;27(12):3043-58.

Pillai S, Govender S. Sacral chordoma : A review of literature. J Orthop. 2018;15(2):679-84.

Yolcu Y, Wahood W, Alvi MA, Kerezoudis P, Okuno SH, Foote RL, et al. Evaluating the Role of Adjuvant Radiotherapy in the Management of Sacral and Vertebral Chordoma: Results from a National Database. World Neurosurg. 2019;127:e1137-44.

Kennamer BT, Gridley DG, Rhines LD, Nair GR, Lettieri SC, Davis KM, et al. Natural History of a Patient with Sacral Chordoma: Case Report and Literature Review. World Neurosurg. 2020;139:132-5.

Whelan JS, Davis LE. Osteosarcoma, Chondrosarcoma, and Chordoma. J Clin Oncol. 2018;36(2):188-93.

Verma S, Vadlamani SP, Shamim SA, Barwad A, Rastogi S, Raj STA. Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma. Clin Sarcoma Res. 2020;10(1):28.

Ferraresi V, Nuzzo C, Zoccali C, Marandino F, Vidiri A, Salducca N, et al. Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. BMC Cancer. 2010;10:22.

Published

2022-12-27

Issue

Section

Relato de Caso

How to Cite

1.
Costa REAR da, Visgueira ARL, Coutinho Neto E de S, Sá CEC de. Metastatic sacral chordoma. Medicina (Ribeirão Preto) [Internet]. 2022 Dec. 27 [cited 2024 Jun. 7];55(4):e-195609. Available from: https://revistas.usp.br/rmrp/article/view/195609